Table 4.
Adjusteda pooled odds ratios (95% confidence intervals) for borderline ovarian cancer in relation to BMI, by histological subtype.
| Studies (n) | Controls (n) | Serous b
|
Mucinous b
|
|||
|---|---|---|---|---|---|---|
| Cases (n) | pOR (95% CI) | Cases (n) | pOR (95% CI) | |||
| Recent BMI | 10 | |||||
| <18.5 | 281 | 23 | 1.12 (0.70–1.79) | 33 | 1.61 (1.08–2.39) | |
| 18.5–24.9 (Ref) | 6599 | 568 | 1.0 | 454 | 1.0 | |
| 25–29.9 | 3930 | 403 | 1.40 (1.22–1.62) | 234 | 1.08 (0.91–1.28) | |
| 30–34.9 | 1741 | 236 | 1.86 (1.55–2.24) | 122 | 1.32 (1.05–1.67) | |
| 35–39.9 | 672 | 101 | 2.11 (1.66–2.70) | 41 | 1.29 (0.91–1.84) | |
| ≥ 40 | 486 | 85 | 2.23 (1.69–2.94) | 41 | 1.68 (1.16–2.43) | |
| Per 5 kg/m2 c | 1.24 (1.18–1.30) | 1.09 (1.02–1.16) | ||||
| Maximum BMI | 7 | |||||
| 18.5–24.9 (Ref) | 2548 | 135 | 1.0 | 138 | 1.0 | |
| 25–29.9 | 2409 | 153 | 1.39 (1.00–1.93) | 113 | 0.99 (0.75–1.30) | |
| 30–34.9 | 1236 | 115 | 2.00 (1.51–2.65) | 78 | 1.39 (0.99–1.96) | |
| 35–39.9 | 544 | 66 | 2.40 (1.71–3.38) | 35 | 1.26 (0.68–2.32) | |
| ≥ 40 | 455 | 71 | 2.73 (1.92–3.88) | 30 | 1.29 (0.79–2.11) | |
| Per 5 kg/m2 c | 1.25 (1.17–1.34) | 1.09 (0.98–1.21) | ||||
| BMI early adulthood | 12 | |||||
| <18.5 | 2718 | 222 | 0.90 (0.77–1.06) | 171 | 1.07 (0.88–1.31) | |
| 18.5–24.9 (Ref) | 11245 | 1034 | 1.0 | 699 | 1.0 | |
| 25–29.9 | 983 | 152 | 1.40 (1.12–1.74) | 86 | 1.22 (0.95–1.55) | |
| 30–34.9 | 210 | 40 | 1.48 (1.03–2.14) | 26 | 1.57 (1.00–2.47) | |
| ≥ 35 | 100 | 29 | 2.34 (1.47–3.74) | 12 | 2.00 (1.00–4.01) | |
| Per 5 kg/m2 c | 1.22 (1.12–1.33) | 1.11 (0.99–1.24) | ||||
a
Stratified by age in 5–year groups and adjusted for parity (0,1,2,3,4+ full–term births), hormonal contraceptive use (0, ≤ 60, >60 months), family history of breast or ovarian cancer in a first degree relative and, where appropriate, race/ethnicity; pooled across study sites using random effects models.
b
Numbers may not sum to total because of missing data
c
Excludes women in the underweight range (BMI < 18.5 kg/m2)